Volume 13, Issue 7, July 2024

Using a decision analytic model, we conducted a cost-effectiveness analysis of management strategies for children with non-severe infectious conjunctivitis compared to usual care in the United States. Usual care was the most expensive strategy, indicating that the economic burden of conjunctivitis could be reduced with a different approach to care.

This systematic review with meta-analysis, which integrated data from 136 studies (172,165 patients), identified diabetes, obesity, immunocompromise, and cardiovascular, neurological, or pulmonary disease as predictors of severe pediatric COVID-19. The presence of multiple comorbidities increases the risk of critical outcomes.

In this work, we demonstrate the safety of 13-valent pneumococcal conjugate vaccine booster dose and the benefits of its administration in terms of protection against pneumococcal disease in children with idiopathic nephrotic syndrome. We propose a possible mechanism behind the reduced immune responses found in these patients.

Telemedicine can be utilized to safely evaluate patients, equitably distribute a scarce resource, and generate wRVUs during pandemics.

After the implementation of nirsevimab in 2023 in France as compared with 2022–2023, we found a 52.7%, (95% CI [46.4–58.9])decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.

International medical graduates (IMGs) in pediatric infectious diseases face unique and complex challenges related to their immigration status. This Perspective provides a review of challenges impacting non-US IMG trainees and early-career faculty, and how the infectious diseases community can respond.

Reporting definitions for Surgical Site Infections (SSIs) are frequently used to identify cases for quality improvement purposes. Here we highlight the discrepancies in reporting criteria for pediatric cardiac surgery procedures and call for alignment in definitions.